Showing results (21-30 of 73) with videos related to
Sort By:
Pageof 8
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten PostmaClinical Therapeutics|September 13, 2005
Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort studyReinhard Sittl, Mark Nuijten, Barbara Poulsen NautrupJournal of Medical Economics|December 21, 2019
A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in ItalyStefano Capri, A Migliore, F Loconsole, et al.Pharmacoeconomics|March 22, 2021
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction SuccessBjörn Schwander, Mark Nuijten, Silvia Evers, et al.Expert Review of Pharmacoeconomics & Outcomes Research|August 30, 2016
Systematic review and overview of health economic evaluation models in obesity prevention and therapyBjoern Schwander, Mickaël Hiligsmann, Mark Nuijten, et al.Clinicoeconomics and Outcomes Research : CEOR|March 21, 2014
Health economic analyses in medical nutrition: a systematic literature reviewStefan Walzer, Daniel Droeschel, Mark Nuijten, et al.Frontiers in Pharmacology|June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and ChallengesHans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.Clinical Therapeutics|September 11, 2007
Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United KingdomHelen Dakin, Mark Nuijten, Hiltrud Liedgens, et al.Clinicoeconomics and Outcomes Research : CEOR|May 31, 2014
Health economics evidence for medical nutrition: are these interventions value for money in integrated care?Stefan Walzer, Daniel Droeschel, Mark Nuijten, et al.Clinicoeconomics and Outcomes Research : CEOR|September 13, 2012
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for ItalyBjoern Schwander, Simona Ravera, Giovanni Giuliani, et al.Pageof 8